Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 6/20 | 0.36 |
| ▸ | SLC1A2 | P43004 | 6/20 | 0.36 |
| ▸ | SLC1A1 | P43005 | 6/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 5/20 | 0.32 |
| ▸ | CNR1 | P21554 | 2/20 | 0.32 |
| ▸ | GSK3B | P49841 | 2/20 | 0.32 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19975294 | 0.86 | NPC1 (0.34) | SLC1A3SLC1A2SLC1A1NPC1RAB9A | |
| SCHEMBL21183564 | 0.82 | CNR2 (0.33) | NPC1RAB9AACACBTDP1CNR2 | |
| SCHEMBL19975017 | 0.82 | TDP1 (0.37) | SLC1A3SLC1A2SLC1A1NPC1RAB9A | |
| SCHEMBL19975356 | 0.82 | TDP1 (0.35) | SLC1A3SLC1A2SLC1A1NPC1RAB9A | |
| SCHEMBL21183542 | 0.77 | TDP1 (0.40) | SLC1A3SLC1A2SLC1A1TDP1 | |
| SCHEMBL21183509 | 0.75 | KMT2A (0.34) | NPC1RAB9AACACBTDP1CNR2 | |
| SCHEMBL19975024 | 0.75 | KMT2A (0.36) | SLC1A3SLC1A2SLC1A1NPC1RAB9A | |
| SCHEMBL21176392 | 0.73 | NPC1 (0.32) | NPC1RAB9ATDP1HTR4 | |
| SCHEMBL19974878 | 0.72 | EPHX1 (0.42) | SLC1A3SLC1A2SLC1A1NPC1RAB9A | |
| SCHEMBL19975218 | 0.71 | CNR2 (0.35) | NPC1RAB9AACACBTDP1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220356148-A1 | ANTIVIRAL COMPOUNDS | HAPLOGEN GMBH (AT) | 2022-11-10 | — | — | US | disclosed |
| US-11091428-B2 | Antiviral compounds | HAPLOGEN GMBH (AT) | 2021-08-17 | — | — | US | disclosed |
| US-11091428-B2 | Antiviral compounds | HAPLOGEN GMBH (AT) | 2021-08-17 | — | — | US | disclosed |
| US-20190225575-A1 | ANTIVIRAL COMPOUNDS | LUNIS CONSULTING GMBH (AT) | 2019-07-25 | — | — | US | disclosed |
| US-20190225575-A1 | ANTIVIRAL COMPOUNDS | LUNIS CONSULTING GMBH (AT) | 2019-07-25 | — | — | US | disclosed |
| EP-3512836-A1 | ANTIVIRAL COMPOUNDS | Haplogen GmbH (AT) | 2019-07-24 | — | — | EP | disclosed |
| WO-2018050631-A1 | ANTIVIRAL COMPOUNDS | HAPLOGEN GMBH (AT) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190225575-A1 | ANTIVIRAL COMPOUNDS | PLA2G1B, PLA2G12A, PLA2G4C | SLC1A3 3943/4885SLC1A2 4457/4885SLC1A1 3975/4885 |
| US-20220356148-A1 | ANTIVIRAL COMPOUNDS | PLA2G12A, PLA2G1B, PLA2G4C | SLC1A3 4195/4885SLC1A2 4584/4885SLC1A1 4221/4885 |
| US-11091428-B2 | Antiviral compounds | PLA2G1B, PLA2G12A, PLA2G4C | SLC1A3 3943/4885SLC1A2 4457/4885SLC1A1 3975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.